With recent incidents of virus contamination in Biopharmaceutical manufactuirng sites, e.g. Mouse minute virus (MMV) or Vesivirus 2117, I believe virus risk mitigation strategies are accelerating in many organizations. Two popular strategies for viral inactivation in liquid media used in biopharmaceutical manufacturing are High Temperature Short Time (HTST) and Ultra Violet Radiation subtype C (UVC) treatment.
Am I imagining this trend or do you see a generalized industry shift to these technologies for lowering risk of viral contamination in cell culture media to be used in bioprocessing? If your organization is pursuing either of these technologies, are there specific support activities from your current media vendors that would assist your organization in implementing these technologies?
Feel free to comment on your view of the current industry situation.
Posted by Bruce Lehr August 20th 2010.
Comments